Literature DB >> 2140088

The role of hyperglycaemia-induced alterations of antithrombin III and factor X activation in the thrombin hyperactivity of diabetes mellitus.

A Ceriello1, A Quatraro, E Marchi, M Barbanti, P Dello Russo, P Lefebvre, D Giugliano.   

Abstract

Factor X concentration and factor X activation, antithrombin III anti-Xa activity and plasma concentration, and fibrinopeptide A were measured in 20 diabetic patients and 20 normal subjects. Although factor X activation (81.3 +/- 2.2 vs 97.3 +/- 2.1%, p less than 0.01; mean +/- SE) and antithrombin III activity (76.5 +/- 2.2 vs 96.3 +/- 1.8%, p less than 0.01) were reduced in the diabetic patients, fibrinopeptide A concentration was increased (3.7 +/- 0.4 vs 1.7 +/- 0.2 ng ml-1, p less than 0.01). The ratio of factor X activation to antithrombin III anti-factor Xa activity was increased in the diabetic patients (1.10 +/- 0.01 vs 1.01 +/- 0.02, p less than 0.01). Induced hyperglycaemia was able to mimic all these abnormalities, without changing factor X or antithrombin III concentration. The results suggest that in vivo hyperglycaemia produces a decrease of factor X activation, but at the same time increases fibrinopeptide A formation due to a greater decrease of antithrombin III anti-Xa activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140088     DOI: 10.1111/j.1464-5491.1990.tb01402.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  7 in total

Review 1.  Hormone replacement therapy in postmenopausal women with diabetes mellitus: a risk-benefit assessment.

Authors:  B Andersson
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

2.  Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay.

Authors:  Armando Tripodi; Adriana Branchi; Veena Chantarangkul; Marigrazia Clerici; Giuliana Merati; Andrea Artoni; Pier Mannuccio Mannucci
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

3.  Effects of factor Xa on the expression of proteins in femoral arteries from type 2 diabetic patients.

Authors:  Antonio J López-Farré; Pablo Rodriguez-Sierra; Javier Modrego; Antonio Segura; Naiara Martín-Palacios; Ana M Saiz; José J Zamorano-León; Juan Duarte; Javier Serrano; Guillermo Moñux
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

Review 4.  Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects.

Authors:  A Ceriello
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

5.  The hyperglycemic byproduct methylglyoxal impairs anticoagulant activity through covalent adduction of antithrombin III.

Authors:  Richard Jacobson; Nicholas Mignemi; Kristie Rose; Lynda O'Rear; Suryakala Sarilla; Heidi E Hamm; Joey V Barnett; Ingrid M Verhamme; Jonathan Schoenecker
Journal:  Thromb Res       Date:  2014-10-05       Impact factor: 3.944

6.  The relationship between insulin sensitivity and serum antithrombin 3 activity in patients with type 2 diabetes.

Authors:  Hong Wang; Jie Cao; Jian-Bin Su; Xue-Qin Wang; Dong-Mei Zhang; Xiao-Hua Wang
Journal:  Endocr Connect       Date:  2021-06-23       Impact factor: 3.335

Review 7.  Coagulatory Defects in Type-1 and Type-2 Diabetes.

Authors:  Amélie I S Sobczak; Alan J Stewart
Journal:  Int J Mol Sci       Date:  2019-12-16       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.